Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD4144 on Rosuvastatin PK in Healthy Participants
NCT06925854Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD4144 in chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from 0 to infinity, Area under the plasma concentration-curve from 0 to the last quantifiable concentration and 1 more. Started Apr 2025; status: completed.
02
Drugs
AZD4144
03
Conditions
chronic kidney disease (CKD)atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06925854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925854.